TOP2B

Across TCGA pan-cancer cohorts, TOP2B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TOP2B data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TOP2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TOP2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and BLCA are the cancer types where TOP2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.184	0.779	<.001	28	view →
UCEC	DFS	Median	All	0.950	0.614	.005	12	view →
BLCA	OS	Median	III,IV	0.243	0.656	.008	12	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TOP2B–LIHC (OS)

Open the LIHC breakdown →